AI-Powered Multi-Protein Blood Test: Detecting Alzheimer’s Like Never Before
Every breakthrough begins with a moment worth remembering. For the founding team of the AI-powered multi-protein blood test technology, that moment came during a scientific conference in the 2010s, when conversations with global neurologists revealed a sobering truth: despite vast neuroscience knowledge, clinics still lacked practical tools to identify and manage Alzheimer’s disease. It was a moment that ignited their mission to turn science into accessible, life-changing care.
Today, that mission has led to Cognitact, spinoff of the Hong Kong University of Science and Technology (HKUST), founded in 2020, licensed with its world first AI-powered multi-protein blood analysis to revolutionise Alzheimer’s detection. It cuts through the barriers of traditional diagnosis – medical history assessments, cognitive tests, invasive brain scans or spinal fluid analysis that are often costly, slow, and inaccessible – offering a simpler, faster, and more affordable way to screen and monitor the disease.
Cognitact’s flagship innovation, PlasmarkAD®, is no ordinary test. Using advanced AI and proteomics, it analyses 22 protein biomarkers from a single blood draw, assessing the status of amyloid proteins in the brain with over 96% accuracy – years before symptoms appear – and potentially identifying an estimated 41 million undiagnosed Alzheimer’s cases worldwide. By enabling earlier screening, proactive intervention, and continuous monitoring, the test delivers timely clinical insights once thought impossible, bringing new hope to patients and families facing the uncertainty of memory loss.
“Keeping up means staying ahead of the curve with purpose, moving fast to test ideas, learn, and turn evidence into better tools for patients and clinicians,” shared the Cognitact team.
The company’s vision goes beyond cognitive health. Their platform is designed to span multiple conditions, ultimately enabling data-driven, long-term care for diseases where early awareness and intervention matter. Over the next five years, they aim to make their blood-based analytics part of routine care, while building partnerships across Asia and globally to make brain health testing widely accessible and affordable.
For many biotech pioneers like Cognitact, innovation sparks from compellingly unforgettable ideas. Join us to “Keep Up for I&T Tomorrow” and turn your scientific discoveries into better healthcare solutions for all.
Source: Cognitact
